HC Wainwright Issues Positive Forecast for FHTX Earnings

Key Points

• HC Wainwright has raised Foghorn Therapeutics' Q3 2025 earnings estimate to ($0.28) per share, signaling a positive shift from their previous estimate of ($0.33).
• The company reported last quarter earnings of ($0.28) EPS, surpassing the consensus estimate by $0.03, despite revenues of $7.56 million falling slightly short of expectations.
• Institutional investors own 61.55% of Foghorn Therapeutics' shares, with Bank of America Corp DE and D.E. Shaw & Co. Inc. significantly increasing their holdings in the company over the last quarter.

Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Stock analysts at HC Wainwright raised their Q3 2025 earnings per share estimates for shares of Foghorn Therapeutics in a research report issued on Wednesday, August 6th. HC Wainwright analyst A. Maldonado now forecasts that the company will earn ($0.28) per share for the quarter, up from their prior estimate of ($0.33). HC Wainwright currently has a "Strong-Buy" rating on the stock. The consensus estimate for Foghorn Therapeutics' current full-year earnings is ($1.55) per share. HC Wainwright also issued estimates for Foghorn Therapeutics' Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.15) EPS, FY2026 earnings at ($1.16) EPS, FY2027 earnings at ($0.99) EPS, FY2028 earnings at ($0.63) EPS and FY2029 earnings at ($0.05) EPS.

A number of other equities research analysts also recently commented on the company. Citizens Jmp initiated coverage on Foghorn Therapeutics in a research report on Wednesday, April 23rd. They set a "mkt outperform" rating and a $9.00 price objective for the company. JMP Securities reiterated a "market outperform" rating and set a $9.00 price objective on shares of Foghorn Therapeutics in a research report on Thursday, May 15th. Finally, Citigroup started coverage on Foghorn Therapeutics in a report on Wednesday, April 23rd. They issued an "outperform" rating for the company. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $12.00.

Foghorn Therapeutics Price Performance

Shares of NASDAQ:FHTX traded down $0.40 on Friday, reaching $4.58. 71,553 shares of the company traded hands, compared to its average volume of 122,213. Foghorn Therapeutics has a fifty-two week low of $2.94 and a fifty-two week high of $10.25. The company's 50 day moving average is $5.13 and its 200-day moving average is $4.59. The stock has a market capitalization of $258.91 million, a PE ratio of -3.85 and a beta of 3.05.

Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.31) by $0.03. The company had revenue of $7.56 million for the quarter, compared to analyst estimates of $7.62 million.

Institutional Trading of Foghorn Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Bank of America Corp DE raised its holdings in shares of Foghorn Therapeutics by 14.5% during the fourth quarter. Bank of America Corp DE now owns 31,662 shares of the company's stock worth $149,000 after acquiring an additional 4,002 shares in the last quarter. D. E. Shaw & Co. Inc. raised its holdings in shares of Foghorn Therapeutics by 44.0% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 100,367 shares of the company's stock worth $474,000 after acquiring an additional 30,671 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Foghorn Therapeutics during the fourth quarter worth $61,000. Lazard Asset Management LLC purchased a new stake in shares of Foghorn Therapeutics during the fourth quarter worth $49,000. Finally, Geode Capital Management LLC raised its holdings in shares of Foghorn Therapeutics by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 682,863 shares of the company's stock worth $3,224,000 after acquiring an additional 5,477 shares in the last quarter. 61.55% of the stock is currently owned by hedge funds and other institutional investors.

Foghorn Therapeutics Company Profile

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.